A phase 2 study evaluating 2-Deoxy-D-glucose (2-DG)
Latest Information Update: 10 Apr 2024
At a glance
- Drugs 2-deoxy-D-glucose (Primary)
- Indications Nose disorders; Rhinovirus infections
- Focus Therapeutic Use
- 10 Apr 2024 According to a G.ST Antivirals media release, Planned number of volunteers to be enrolled in this trial is 128.
- 09 Apr 2024 According to a G.ST Antivirals media release, company announced the appointment of Ronald Bruce Turner, MD, as new Chief Medical Officer (CMO).
- 09 Apr 2024 According to a G.ST Antivirals media release, first subject was dosed on April 2nd, 2024